INM

InMed Pharmaceuticals Inc. (INM) Business Model Analysis (2026)

Invetso Score: 4.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Value Proposition Revenue Model

Score: 4.2 (Moderate)

R&D-led product model: Revenue is driven by development-heavy offerings, with R&D at 65.2% of revenue, indicating a product model that depends on sustained innovation.

Low asset intensity: Capex is negligible relative to revenue, supporting a light physical footprint and limiting fixed-asset drag on scaling.

High compensation burden: Stock-based compensation at 11.3x revenue indicates value capture is structurally diluted, pressuring economic quality versus peers.

Cost Structure

Score:

R&D dominates cost base: R&D intensity near revenue scale creates a structurally heavy operating cost base, limiting near-term margin conversion.

Equity compensation is extreme: Stock-based compensation far above revenue signals material non-cash dilution, weakening per-share economics versus peers.

Limited operating cash conversion: Income quality of 0.0024 implies very weak earnings-to-cash conversion, reducing cost flexibility and financial resilience.

Scalability Operating Leverage

Score:

Asset-light scaling: Low capex supports revenue growth without proportional fixed-asset investment, improving theoretical scalability.

Operating leverage remains constrained: High R&D and compensation intensity mean incremental revenue is unlikely to translate quickly into margin expansion.

Peer scaling profile is weaker: Compared with more mature software peers, the model appears less efficient because growth still requires heavy internal spend.

Customer Structure Concentration

Score:

Customer mix not disclosed in metrics: Available data does not show customer concentration, limiting visibility into revenue dependence and renewal risk.

Model likely broad but unproven: The product-led structure suggests diversified demand, but the absence of disclosed concentration data prevents a stronger score.

Revenue Quality Predictability

Score:

Cash conversion is very weak: Income quality near zero indicates reported earnings are not translating into cash, reducing revenue reliability.

Dilution lowers revenue quality: Very high stock-based compensation weakens the durability of economic returns even if top-line growth persists.

Predictability remains limited: Heavy development spending and weak cash conversion make multi-year revenue quality less predictable than stronger peer models.

Overall Score

Score:

INM’s model is asset-light and R&D-driven, but extreme compensation intensity and very weak cash conversion materially limit scalability and predictability.

Score Driver: The Dominant Structural Constraint Is Poor Economic Quality From Extreme Stock-Based Compensation And Weak Cash Conversion, Which Outweighs The Asset-Light Scaling Benefit.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on InMed Pharmaceuticals Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →